Tampere University of Technology

TUTCRIS Research Portal

MicroRNA in prostate, bladder, and kidney cancer: A systematic review

Research output: Contribution to journalReview ArticleScientificpeer-review

Standard

MicroRNA in prostate, bladder, and kidney cancer : A systematic review. / Catto, James W.F.; Alcaraz, Antonio; Bjartell, Anders S.; De Vere White, Ralph; Evans, Christopher P.; Fussel, Susanne; Hamdy, Freddie C.; Kallioniemi, Olli; Mengual, Lourdes; Schlomm, Thorsten; Visakorpi, Tapio.

In: European Urology, Vol. 59, No. 5, 05.2011, p. 671-681.

Research output: Contribution to journalReview ArticleScientificpeer-review

Harvard

Catto, JWF, Alcaraz, A, Bjartell, AS, De Vere White, R, Evans, CP, Fussel, S, Hamdy, FC, Kallioniemi, O, Mengual, L, Schlomm, T & Visakorpi, T 2011, 'MicroRNA in prostate, bladder, and kidney cancer: A systematic review', European Urology, vol. 59, no. 5, pp. 671-681. https://doi.org/10.1016/j.eururo.2011.01.044

APA

Catto, J. W. F., Alcaraz, A., Bjartell, A. S., De Vere White, R., Evans, C. P., Fussel, S., ... Visakorpi, T. (2011). MicroRNA in prostate, bladder, and kidney cancer: A systematic review. European Urology, 59(5), 671-681. https://doi.org/10.1016/j.eururo.2011.01.044

Vancouver

Catto JWF, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S et al. MicroRNA in prostate, bladder, and kidney cancer: A systematic review. European Urology. 2011 May;59(5):671-681. https://doi.org/10.1016/j.eururo.2011.01.044

Author

Catto, James W.F. ; Alcaraz, Antonio ; Bjartell, Anders S. ; De Vere White, Ralph ; Evans, Christopher P. ; Fussel, Susanne ; Hamdy, Freddie C. ; Kallioniemi, Olli ; Mengual, Lourdes ; Schlomm, Thorsten ; Visakorpi, Tapio. / MicroRNA in prostate, bladder, and kidney cancer : A systematic review. In: European Urology. 2011 ; Vol. 59, No. 5. pp. 671-681.

Bibtex - Download

@article{21941425109646ba852129a0f0c9f5d8,
title = "MicroRNA in prostate, bladder, and kidney cancer: A systematic review",
abstract = "Context: MicroRNAs (miRNA) are noncoding RNAs that post-transcriptionally regulate gene expression. Their altered expression and function have been observed in most urologic cancers. MiRNAs represent potential disease biomarkers and novel therapeutic targets. Objective: To review and evaluate the evidence implicating miRNAs in the pathogenesis of prostate cancer (PCa), bladder cancer (BCa), and renal cancer. Evidence acquisition: A systematic review was performed using PubMed and Embase to search for reports using strings for microRNA, non-coding RNA, cancer, prostate, bladder, and renal cancer. Identified manuscripts were retrieved and references searched. Selected studies were required to concentrate on the role of miRNA in these urologic cancers. Evidence synthesis: We reviewed articles that focus on this topic. More than 40 miRNAs have been implicated in urologic cancer and many target common carcinogenic pathways. In particular, apoptosis avoidance, cell proliferation, epithelial-to-mesenchymal transition, angiogenic signalling, and the generation of androgen independence are targeted or facilitated by more than one miRNA. Little work has been done to evaluate the translational applications for this knowledge to date. Novel therapeutic strategies have been developed and are under investigation to selectively modulate miRNAs; such work would potentially enable personalised tumour therapy. Conclusions: MiRNAs appear to be important modulators of urologic cancer. Their expression is frequently altered in these tumours, and many are functionally implicated in their pathogenesis. They require evaluation to determine the translational role and therapeutic potential for this knowledge.",
keywords = "Bladder, Cancer, Gene regulation, Kidney, MicroRNA, Prostate",
author = "Catto, {James W.F.} and Antonio Alcaraz and Bjartell, {Anders S.} and {De Vere White}, Ralph and Evans, {Christopher P.} and Susanne Fussel and Hamdy, {Freddie C.} and Olli Kallioniemi and Lourdes Mengual and Thorsten Schlomm and Tapio Visakorpi",
year = "2011",
month = "5",
doi = "10.1016/j.eururo.2011.01.044",
language = "English",
volume = "59",
pages = "671--681",
journal = "European Urology",
issn = "0302-2838",
publisher = "Elsevier",
number = "5",

}

RIS (suitable for import to EndNote) - Download

TY - JOUR

T1 - MicroRNA in prostate, bladder, and kidney cancer

T2 - A systematic review

AU - Catto, James W.F.

AU - Alcaraz, Antonio

AU - Bjartell, Anders S.

AU - De Vere White, Ralph

AU - Evans, Christopher P.

AU - Fussel, Susanne

AU - Hamdy, Freddie C.

AU - Kallioniemi, Olli

AU - Mengual, Lourdes

AU - Schlomm, Thorsten

AU - Visakorpi, Tapio

PY - 2011/5

Y1 - 2011/5

N2 - Context: MicroRNAs (miRNA) are noncoding RNAs that post-transcriptionally regulate gene expression. Their altered expression and function have been observed in most urologic cancers. MiRNAs represent potential disease biomarkers and novel therapeutic targets. Objective: To review and evaluate the evidence implicating miRNAs in the pathogenesis of prostate cancer (PCa), bladder cancer (BCa), and renal cancer. Evidence acquisition: A systematic review was performed using PubMed and Embase to search for reports using strings for microRNA, non-coding RNA, cancer, prostate, bladder, and renal cancer. Identified manuscripts were retrieved and references searched. Selected studies were required to concentrate on the role of miRNA in these urologic cancers. Evidence synthesis: We reviewed articles that focus on this topic. More than 40 miRNAs have been implicated in urologic cancer and many target common carcinogenic pathways. In particular, apoptosis avoidance, cell proliferation, epithelial-to-mesenchymal transition, angiogenic signalling, and the generation of androgen independence are targeted or facilitated by more than one miRNA. Little work has been done to evaluate the translational applications for this knowledge to date. Novel therapeutic strategies have been developed and are under investigation to selectively modulate miRNAs; such work would potentially enable personalised tumour therapy. Conclusions: MiRNAs appear to be important modulators of urologic cancer. Their expression is frequently altered in these tumours, and many are functionally implicated in their pathogenesis. They require evaluation to determine the translational role and therapeutic potential for this knowledge.

AB - Context: MicroRNAs (miRNA) are noncoding RNAs that post-transcriptionally regulate gene expression. Their altered expression and function have been observed in most urologic cancers. MiRNAs represent potential disease biomarkers and novel therapeutic targets. Objective: To review and evaluate the evidence implicating miRNAs in the pathogenesis of prostate cancer (PCa), bladder cancer (BCa), and renal cancer. Evidence acquisition: A systematic review was performed using PubMed and Embase to search for reports using strings for microRNA, non-coding RNA, cancer, prostate, bladder, and renal cancer. Identified manuscripts were retrieved and references searched. Selected studies were required to concentrate on the role of miRNA in these urologic cancers. Evidence synthesis: We reviewed articles that focus on this topic. More than 40 miRNAs have been implicated in urologic cancer and many target common carcinogenic pathways. In particular, apoptosis avoidance, cell proliferation, epithelial-to-mesenchymal transition, angiogenic signalling, and the generation of androgen independence are targeted or facilitated by more than one miRNA. Little work has been done to evaluate the translational applications for this knowledge to date. Novel therapeutic strategies have been developed and are under investigation to selectively modulate miRNAs; such work would potentially enable personalised tumour therapy. Conclusions: MiRNAs appear to be important modulators of urologic cancer. Their expression is frequently altered in these tumours, and many are functionally implicated in their pathogenesis. They require evaluation to determine the translational role and therapeutic potential for this knowledge.

KW - Bladder

KW - Cancer

KW - Gene regulation

KW - Kidney

KW - MicroRNA

KW - Prostate

UR - http://www.scopus.com/inward/record.url?scp=79953249325&partnerID=8YFLogxK

U2 - 10.1016/j.eururo.2011.01.044

DO - 10.1016/j.eururo.2011.01.044

M3 - Review Article

VL - 59

SP - 671

EP - 681

JO - European Urology

JF - European Urology

SN - 0302-2838

IS - 5

ER -